377 FGFR protein phosphorylation as a biomarker for FGFR-targeted therapy in cholangiocarcinoma
Zachary Risch, Julie Reeser, Michele Wing, Amy Smith, Thuy Dao, Eric Samorodnitsky, Emanuel Petricoin, Sameek Roychowdhury · 2026
Read 377 FGFR protein phosphorylation as a biomarker for FGFR-targeted therapy in cholangiocarcinoma by Zachary Risch, Julie Reeser, Michele Wing, Amy Smith, Thuy Dao, Eric Samorodnitsky, Emanuel Petricoin, Sameek Roychowdhury (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13173027.txt.
Description
Zachary Risch and seven co-authors test a protein signal as a guide for targeted therapy in cholangiocarcinoma, an aggressive bile duct cancer. FGFR2 fusions can be drugged, but they appear in only about 20% of cases, which limits who benefits. The team used reverse phase protein arrays on tumors from 24 patients in a registry study. Twelve tumors had FGFR2 fusions, four had other FGFR2 changes, and eight were wildtype.
Phosphorylation at the FGFR2 site Y653.654 did not differ between altered and wildtype tumors. CD3 protein, though, ran much lower in FGFR-altered tumors. The authors read that gap as a possible sign of a distinct immune setting in those tumors.
Catalog record
| CREATOR | Zachary Risch, Julie Reeser, Michele Wing, Amy Smith, Thuy Dao, Eric Samorodnitsky, Emanuel Petricoin, Sameek Roychowdhury |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |